Arius announces new findings in Trop-2 and CD59 CANCER antibody programs

    - CD59 antibody uses novel approach to "de-cloak" cancers -

    TORONTO, Oct. 25 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that new findings have been presented from its Trop-2 and CD59
antibody programs. ARIUS scientists will discuss the Company's Trop-2 and CD59
abstracts at the AACR press conference today at 9:30 a.m. PT.
    "Both our Trop-2 and CD59 antibody programs have demonstrated novel
approaches in treating cancer. Our Trop-2 antibody is a novel target and has
been linked to aggressive cancers in the scientific literature, while our CD59
program has demonstrated the ability to foil a cancer cell's ability to evade
the immune system," said Dr. David Young, President and CEO. "These programs,
in addition to our CD44 cancer stem cell program, were generated through our
proprietary drug discovery technology, FunctionFIRST(TM), which is inherently
designed to produce novel antibodies and identify unique cancer targets."

    Trop-2 Proffered Paper Presentation

    ARIUS' Trop-2 targeting antibody has demonstrated a significant
anti-tumor effect in animal models of human pancreatic cancer, inhibiting
tumor growth by up to 100 percent. Subsequent testing showed efficacy in
animal models of breast, colon and prostate cancers. The antibody compared
favorably with Taxotere in prostate cancer model and has also shown the
ability to be highly potent at low-dose concentrations.
    Additional information can be found at the AACR-NCI-EORTC 2007
International Conference on Molecular Targets and Cancer Therapeutics in San
Francisco at the following location and time: AR47A6.4.2, a functional naked
monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human
pancreatic, colon, breast and prostate cancer models. Proffered Paper Session
3, Thursday, October 25, 2007 from 5:15 - 5:30 p.m. in the Third Floor
Ballroom at Moscone Center.

    CD59 Poster Presentation

    ARIUS has demonstrated that CD59 is commonly used to protect cancer cells
from being destroyed. Our CD59 targeting antibody provides a novel approach to
"de-cloak" cancers. The CD59 targeting antibody activates complement activity
against cancer cells and inhibits tumor growth in animal models of breast,
colon, lung and prostate. In animal models of breast cancer, tumor growth was
inhibited by up to 100 percent. In particular, the potent effect was observed
in breast cancer models that represent a patient population that cannot be
treated by Herceptin, the only therapeutic antibody currently approved for
breast cancer treatment.
    ARIUS' CD59 poster was presented at the AACR-NCI-EORTC 2007 International
Conference on Molecular Targets and Cancer Therapeutics in San Francisco on
Tuesday October 23, 2007 and is entitled "AR36A36.11.1, a monoclonal antibody
targeting CD59, enhances complement activity and exhibits potent in vivo
efficacy in multiple human cancer models."
    ARIUS scientists Dr. Amandine Truong, Ph.D. and Dr. Baldwin Mak, Ph.D.
will discuss the Company's findings for the aforementioned two abstracts at
the AACR press conference on Thursday, October 25th at 9:30 a.m. PT.

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00013708E

For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,,; James Smith, Investor
Relations, (416) 815-0700 ext. 229,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890